Abstract PTH-014 Table 1  Outcome of 1st PPS episode, by risk group at screening

<table>
<thead>
<tr>
<th>Outcome of 1st PPS</th>
<th>No adenoma</th>
<th>LR</th>
<th>IR</th>
<th>HR</th>
<th>CRC</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR at screening</td>
<td>proportion (95% CI)</td>
<td>0.39</td>
<td>0.37</td>
<td>0.15</td>
<td>0.08</td>
</tr>
<tr>
<td></td>
<td>n</td>
<td>8225</td>
<td>7821</td>
<td>3161</td>
<td>1651</td>
</tr>
<tr>
<td>IR at screening</td>
<td>proportion (95% CI)</td>
<td>0.56</td>
<td>0.32</td>
<td>0.08</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>n</td>
<td>12 869</td>
<td>7422</td>
<td>1766</td>
<td>755</td>
</tr>
</tbody>
</table>

Abstract PTH-014 Figure 1  Surveillance episodes by year

Abstract PTH-014 Figure 2  Screening category, age & gender

Abstracts

A UNIVERSITY HOSPITAL EXPERIENCE OF UPPER GI BLEEDING IN PATIENTS ON NOVEL ORAL ANTICOAGULANTS

Adam McCulloch*, Patrick McDowell, Sam Smith, Ralph Boulton. University Hospital Birmingham NHS Foundation Trust, Edgbaston, UK

10.1136/gutjnl-2018-BSGAbstracts.37

Introduction

The novel oral anticoagulants (NOACs), are increasingly favoured over conventional anticoagulants given their convenience and reduced drug interactions. Although NOACs have a favourable safety profile, the innate risk of haemorrhagic complications, including upper gastrointestinal bleeding (UGIB) is still a concern in high-risk patients. In light of this, we reviewed the outcomes of UGIB in patients on NOACs in our institution and compared them to patients not receiving any anticoagulation.

Methods

We identified inpatients on NOACs from a prospectively collected audit of 680 consecutive gastroscopies performed in 600 patients with UGIB between 1 August 2016 to 30 November 2017.

Results

(NOAC patients): 42 patients (avg age 76.8 years, range 36–91, 50% female) on NOACs underwent a gastroscopy for UGIB, 32 on Apixiban and 10 on Rivaroxaban. Nine (21.4%) were co-prescribed antiplatelet agents. Most common indications for anticoagulation were atrial fibrillation (78.6%) followed by thromboembolic disease (21.4%).

12 patients (28.6%) required endotherapy, with the most commonly encountered pathology being duodenal ulceration, followed by gastric ulceration. Four patients re-bled, all of whom underwent repeat gastroscopy where definitive haemostasis was achieved.

Six patients (14.3%) died within 30 days of their gastroscopy (avg age 82.2 years, range 73–88), 3 as a direct result of an UGIB. All deaths occurred in patients with multiple comorbidities.

Comparison to group without anticoagulation:

Patients on NOACs were older (76.8 years vs 63.9 years, p-value 0.0001), had slightly higher rebleed rates (9.5% vs 8.3%) and had a trend to higher UGIB related 30 day mortality rate (7.1% vs 2.4%).

Conclusions

1. A portion of patients on NOACs died as a direct consequence of GI bleeding.
2. All deaths occurred in elderly patients with multiple comorbid illnesses emphasising the importance of robust patient selection in NOAC prescription.
3. To date Dabigatran is the only NOAC with a licenced reversal agent, Idarucizumab. Until reversal agents are available for the other NOACs perhaps Dabigatran should be preferentially considered in high risk patients despite its limitations and bleeding risk.

TUNNEL BIOPSY IS AN UNDERUTILISED, SIMPLE AND SAFE METHOD FOR TISSUE ACQUISITION IN SUBEPITHELIAL TUMOURS


10.1136/gutjnl-2018-BSGAbstracts.38

Introduction

Tissue acquisition from subepithelial lesions is most often attempted by EUS-guided fine needle aspiration/biopsy as conventional endoscopic biopsy usually fails to reach the lesion in deeper layers of the gastrointestinal wall. Tunnelled biopsy, a ‘bite-on-bite’ biopsy technique that penetrates
the covering mucosa by repeated biopsies, enables access to tumours below the mucosa.

We investigated the utilisation, safety and diagnostic yield of an intensified tunnel biopsy protocol.

**Methods** The endoscopy reporting database was searched for patients with reported subepithelial lesions in the upper gastrointestinal tract from March 2013 to September 2017.

The tunnel biopsy protocol was defined as bite-on-bite technique from the identical spot creating a submucosal tunnel, taking at least 10 passes of double biopsies with a standard biopsy forceps, while targeting the subepithelial lesion.

Patient records were reviewed for histology reports, imaging studies, adverse events and readmissions after endoscopy.

**Results** 152 patients (70 M, 82 F) were found to have at least one subepithelial lesion at upper endoscopy with a median lesion size of 12 mm (interquartile range 9–23 mm). Superficial conventional biopsies were taken in 79 patients and were diagnostic only for one lipoma (1.3%). Tunnel biopsies were taken in 71/152 patients (47.4%). Sites were oesophagus (9), stomach (58) and duodenum (4). Tunnel biopsies were diagnostic in 31/71 (43.6%), revealing 9 leiomyomas, 1 leiomyosarcoma, 7 lipomas, 2 pancreatic rests, 10 GISTs, 1 retention cyst and 1 fibrotic nodule.

For lesions ≥ 20 mm the diagnostic yield of tunnel biopsies further increased to 16/28 (57.0%). There was no major immediate adverse event or 30 day readmission related to delayed complications from the procedure.

Only two of the 36 endoscopists involved in this study routinely performed tunnel biopsies from subepithelial lesions. Attempting tissue acquisition via tunnel biopsy was significantly more likely to achieve diagnostic histology than by superficial biopsies (p<0.00001).

**Conclusions** Tunnel biopsy is a simple, safe and reasonably efficient diagnostic modality for tissue acquisition in subepithelial lesions in the upper gastrointestinal tract. This technique is still underutilised and should be routinely attempted if a subepithelial lesion is detected at the index endoscopy.

**IS DYSPHAGIA UNDER INVESTIGATED AT ENDOSCOPY?**

Georgina Chadwick*, Jonathan Hoare. St Marys Hospital, London, UK

10.1136/gutjnl-2018-BSGAbstracts.40

**Introduction** Minimally invasive, endoscopic therapies (radiofrequency ablation (RFA)) with/without endoscopic resection (ER)) are widely performed for early Barrett’s-associated neoplasia (dysplasia or intramucosal carcinoma) and appear to be effective in the short term. There is however, a paucity of longer term outcomes including overall survival, in a cohort of patients who are often significantly co-morbid or increasingly elderly. We aim to study and overall survival (OS) in a cohort of patients with early neoplasia in Barrett’s oesophagus (BO-EN) treated since 2008.

**Methods** A retrospective audit of a cohort of patients receiving RFA for BO-EN, of any length, at the Ninewells Hospital and Medical School was analysed. Between December 2008 and January 2018; 39 patients were undergoing/completed treatment and engaged in active surveillance.

These patients were assessed for baseline demographics, duration of follow up and mortality, with a future directive being the assessment of complete resolution of both BO-EN and Barrett’s Oesophagus – Intestinal Metaplasia (BE-IM).

**Results** In total, we have a completed cohort of 39 patients with absolute dataset who have undergone treatment. Of our population; 27 (69%) are male with the remaining 12 (31%) being female with a median age of 67 (Range 44–82 years). Patients were followed up for a median of 42 months (Range 1–172).

A total of 39, 27 and 17 patients were included in the baseline (<1 year post therapy), 3 year and 5 year analyses, respectively. The presenting histology was Low-Grade Dysplasia (LGD) – 8 (21%), High-Grade Dysplasia (HGD)– 22 (56%) and Carcinoma In-Situ – 9 (23%).

Overall survival at 1, 3 and 5 years was 100%, with no progression to overt invasive malignancy demonstrated within this populace.

**Conclusions** RFA (with/without ER) appears to be effective at controlling BO-EN and preventing progression to invasive adenocarcinoma, with a sustained effect appreciable to at least 5 years and possibly beyond.

Not unsurprisingly men appear to develop higher grades of dysplasia; at younger ages, this is consistent with known risk bias within the published literature (Average age at diagnosis; M=65 years vs F=81).

Our data suggests that despite the considerable comorbidity of these individuals, the intervention is well tolerated, with minimal deleterious sequelae and good survival prospects, albeit in a small sample size.

We aim to continue to expand the dataset prospectively and actively record the capability for RFA treatment to completely reverse underlying intestinal metaplasia in this group.